GlassScriptPhysician profile
David M Nierenberg
NPI 1851352512
$6,503.15
in general payments reported to CMS, 2019-2025
49 companies · $439 in 2025
The $439 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,243 · 2020: $1,248 · 2021: $1,635 · 2022: $810 · 2023: $679 · 2024: $449 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,566.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $809.78 | 2019-2024 | Repatha, Otezla, Prolia |
| Abbvie INC. | $540.50 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $521.49 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $472.86 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $465.38 | 2019-2025 | Farxiga, Airsupra |
| Amarin Pharma, INC. | $364.61 | 2019-2022 | |
| Pfizer INC. | $356.21 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $311.10 | 2019-2021 | |
| Glaxosmithkline, LLC. | $223.37 | 2020-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.96 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $193.91 | 2019-2024 | Trintellix |
| Allergan, INC. | $187.58 | 2020-2021 | |
| Boston Scientific Corporation | $167.00 | 2019 | |
| Azurity Pharmaceuticals, INC. | $161.34 | 2023-2025 | Horizant, Azmiro, Edarbi |
| Novartis Pharmaceuticals Corporation | $136.49 | 2019-2025 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Nierenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.